Identification of an AKT-dependent signalling pathway that mediates tamoxifen-dependent induction of the pro-metastatic protein anterior gradient-2
Language English Country Ireland Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
Biotechnology and Biological Sciences Research Council - United Kingdom
PubMed
23354592
DOI
10.1016/j.canlet.2013.01.034
PII: S0304-3835(13)00077-3
Knihovny.cz E-resources
- MeSH
- Antineoplastic Agents, Hormonal pharmacology MeSH
- Humans MeSH
- MicroRNAs MeSH
- Molecular Sequence Data MeSH
- Mucoproteins MeSH
- Cell Line, Tumor MeSH
- Breast Neoplasms drug therapy metabolism pathology MeSH
- Oncogene Proteins MeSH
- Protein Serine-Threonine Kinases metabolism MeSH
- 3-Phosphoinositide-Dependent Protein Kinases MeSH
- Proteins genetics metabolism MeSH
- Proto-Oncogene Proteins c-akt metabolism MeSH
- Ribonucleosides pharmacology MeSH
- Base Sequence MeSH
- Serine metabolism MeSH
- Signal Transduction drug effects MeSH
- Tamoxifen pharmacology MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- AGR2 protein, human MeSH Browser
- Antineoplastic Agents, Hormonal MeSH
- MicroRNAs MeSH
- Mucoproteins MeSH
- Oncogene Proteins MeSH
- PDPK1 protein, human MeSH Browser
- Protein Serine-Threonine Kinases MeSH
- 3-Phosphoinositide-Dependent Protein Kinases MeSH
- Proteins MeSH
- Proto-Oncogene Proteins c-akt MeSH
- Ribonucleosides MeSH
- Serine MeSH
- Tamoxifen MeSH
- triciribine MeSH Browser
The pro-metastatic protein anterior gradient-2 (AGR2) was previously demonstrated as a predictive factor of poor response to tamoxifen treatment. In this study we aimed to delineate the key signalling pathway that may contribute to regulation of AGR2 protein induction in order to identify novel targets to overcome tamoxifen resistance in tumour cells. Together, our data identify PDPK1-AKT as a pro-oncogenic signalling pathway that triggers AGR2 protein induction in response to tamoxifen and suggest that AKT inhibitors could be used as part of a therapeutic strategy to treat tamoxifen resistant, AGR2 over-expressing cancers.
References provided by Crossref.org
AGR2 predicts tamoxifen resistance in postmenopausal breast cancer patients
